Dapagliflozin DAPA-MI Phase III — PatSnap Eureka
Dapagliflozin DAPA-MI: SGLT2 Expansion into Acute Myocardial Infarction
AstraZeneca's selective SGLT2 inhibitor dapagliflozin — proven in heart failure and diabetic kidney disease — is now under Phase III investigation in post-MI patients irrespective of diabetes status. Explore the patent and clinical intelligence landscape with PatSnap Eureka.
Dapagliflozin Indication Expansion: Approved vs. Investigational
DAPA-MI Phase III represents the first SGLT2 inhibitor investigation in acute MI, expanding beyond established HF and DKD approvals.
From HF and DKD to Acute MI: The SGLT2 Inhibitor Frontier
Dapagliflozin is AstraZeneca's selective SGLT2 (sodium-glucose cotransporter-2) inhibitor that has demonstrated clinical benefit in heart failure (HF) and diabetic kidney disease (DKD). These established indications have prompted investigation of its cardioprotective potential in a new and clinically significant setting: acute myocardial infarction (AMI).
The AMI population has historically been underserved by the SGLT2 inhibitor drug class. The DAPA-MI Phase III program represents a strategic expansion into acute cardiovascular intervention, with a notable design feature: it targets post-MI patients irrespective of diabetes status. This broadens the potential eligible population significantly beyond the typical SGLT2i prescribing context.
Regulatory agencies including the US FDA and the European Medicines Agency have already approved dapagliflozin across multiple cardiometabolic indications, establishing a regulatory precedent that DAPA-MI seeks to extend. Meanwhile, ClinicalTrials.gov hosts NCT identifiers associated with the DAPA-MI program that researchers can query for enrolment and endpoint data.
For IP professionals and R&D teams tracking this therapeutic space, patent landscape analysis across AstraZeneca's cardiovascular filing families offers a critical lens on the competitive dynamics and freedom-to-operate considerations surrounding SGLT2i expansion into AMI.
Why SGLT2 Inhibition in Acute Myocardial Infarction?
The DAPA-MI program builds on dapagliflozin's established cardioprotective profile to address an unmet need in post-infarction care.
Selective SGLT2 Inhibition
Dapagliflozin is a selective SGLT2 (sodium-glucose cotransporter-2) inhibitor. The SGLT2 inhibitor class has demonstrated clinical benefit in heart failure and diabetic kidney disease, establishing a cardioprotective mechanistic foundation that underpins the DAPA-MI hypothesis.
Sodium-glucose cotransporter-2Proven Benefit in HF and DKD
Prior to DAPA-MI, dapagliflozin had demonstrated clinical benefit in heart failure (HF) and diabetic kidney disease (DKD). These approvals provided the evidentiary basis for investigating cardioprotective potential in the acute MI setting.
HF · DKD · T2D approvedPost-MI Patients Irrespective of Diabetes
A defining feature of the DAPA-MI Phase III program is its enrolment of post-MI patients irrespective of diabetes status. This design targets a population historically underserved by the SGLT2 inhibitor class and broadens the potential therapeutic reach of dapagliflozin.
Non-diabetic AMI populationAcute Cardiovascular Intervention
The DAPA-MI Phase III program represents a strategic expansion of the SGLT2 inhibitor class into acute cardiovascular intervention — a setting distinct from the chronic disease management context in which SGLT2 inhibitors have historically been studied and approved.
Acute cardiovascular interventionDAPA-MI Research Dimensions & Search Strategy
Understanding the patent and literature search dimensions for dapagliflozin's AMI expansion helps researchers identify gaps and prioritise intelligence queries.
DAPA-MI Intelligence Search Dimensions
Three planned search dimensions span core mechanisms, clinical application, and assignee strategy for comprehensive SGLT2i AMI coverage.
SGLT2 Inhibitor Indication Status Distribution
Dapagliflozin's approved indications (T2D, HF, DKD) versus its investigational AMI program, illustrating the class expansion trajectory.
What DAPA-MI Means for the SGLT2 Inhibitor Landscape
The DAPA-MI Phase III program carries strategic implications for AstraZeneca, competitor SGLT2i developers, and the broader cardiovascular pharmacology field.
Acute MI: An Underserved SGLT2i Population
The acute myocardial infarction setting has historically been underserved by the SGLT2 inhibitor class. DAPA-MI's Phase III design directly addresses this gap, targeting post-MI patients in an acute cardiovascular intervention context distinct from chronic disease management.
Non-Diabetic Enrolment Broadens Reach
By enrolling post-MI patients irrespective of diabetes status, DAPA-MI expands the potential eligible population beyond the typical SGLT2 inhibitor prescribing context. This design choice reflects the cardioprotective hypothesis rather than a glycaemic management rationale.
Recommended Actions for DAPA-MI Intelligence
The following actions are recommended to build comprehensive patent and clinical intelligence on dapagliflozin's acute MI expansion program.
Retry with Alternative SGLT2i Query Strategies
Retry searches with alternative query strategies targeting SGLT2i cardiovascular outcomes, sodium-glucose cotransporter-2 AMI, or dapagliflozin post-infarction trials to capture the full breadth of relevant patent and literature records.
SGLT2i cardiovascular outcomesVerify 2020–2025 Database Index Coverage
Verify that the patent database index covers clinical trial literature and cardiovascular pharmacology filings for the 2020–2025 window — the period most relevant to the DAPA-MI Phase III program's development and filing activity.
2020–2025 cardiovascular filingsQuery ClinicalTrials.gov for DAPA-MI NCT Identifiers
Supplement patent searches with a direct ClinicalTrials.gov query for NCT identifiers associated with DAPA-MI to capture clinical trial registration data not indexed in standard patent databases.
NCT identifiers · clinical registrySearch USPTO/EPO for AstraZeneca Cardiovascular Families
Consider supplementing with direct USPTO and EPO searches under AstraZeneca cardiovascular patent families to identify SGLT2 inhibitor filings relevant to the acute MI setting that may not surface through literature-only queries. PatSnap Analytics provides integrated access to both office databases.
USPTO · EPO · AstraZeneca familiesExecute All Four Actions in PatSnap Eureka
One platform for patent search, clinical trial signals, and assignee landscape — purpose-built for life sciences R&D teams.
Dapagliflozin DAPA-MI Phase III — key questions answered
The DAPA-MI Phase III program is a clinical investigation of dapagliflozin, AstraZeneca's selective SGLT2 inhibitor, in the acute myocardial infarction setting. It represents a strategic expansion of the SGLT2 inhibitor class into acute cardiovascular intervention, targeting post-MI patients irrespective of diabetes status.
Dapagliflozin is AstraZeneca's selective SGLT2 (sodium-glucose cotransporter-2) inhibitor. It has demonstrated clinical benefit in heart failure (HF) and diabetic kidney disease (DKD), and is now under investigation for its cardioprotective potential in the acute myocardial infarction setting.
Following demonstrated clinical benefit in heart failure and diabetic kidney disease, AstraZeneca is investigating dapagliflozin's cardioprotective potential in the acute myocardial infarction setting — a population historically underserved by this drug class — through the DAPA-MI Phase III program.
Yes. The DAPA-MI Phase III program targets post-MI patients irrespective of diabetes status, which is a notable expansion of the typical SGLT2 inhibitor indication profile that has historically focused on patients with type 2 diabetes, heart failure, or diabetic kidney disease.
Dapagliflozin belongs to the SGLT2 inhibitor (SGLT2i) drug class — sodium-glucose cotransporter-2 inhibitors. This class has established indications in heart failure (HF) and diabetic kidney disease (DKD), with DAPA-MI representing an expansion into acute cardiovascular intervention.
PatSnap Eureka provides AI-powered patent and literature intelligence across cardiovascular pharmacology, SGLT2 inhibitor filings, and clinical trial signals. Researchers can query SGLT2i cardiovascular outcomes, sodium-glucose cotransporter-2 AMI data, and AstraZeneca patent families to accelerate drug discovery and competitive intelligence workflows.
Still have questions about dapagliflozin or SGLT2 inhibitor patent intelligence? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka NowAccelerate Your SGLT2 Inhibitor & Cardiovascular R&D Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Search DAPA-MI patent families, AstraZeneca cardiovascular filings, and SGLT2i clinical trial signals in one AI-powered platform.
References
- ClinicalTrials.gov — DAPA-MI NCT Identifiers, US National Library of Medicine
- US Food and Drug Administration (FDA) — Dapagliflozin Approved Indications
- European Medicines Agency (EMA) — SGLT2 Inhibitor Regulatory Approvals
- PatSnap Analytics — Patent Landscape Analysis for Cardiovascular Pharmacology
- PatSnap Life Sciences Intelligence Platform
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. The DAPA-MI program description is derived from AstraZeneca's published clinical development programme disclosures.
PatSnap Eureka searches patents and research to answer instantly.